All Stories

  1. Disruption of cholesterol homeostasis by antidepressants induces immunogenic cell death

    Article • OncoImmunology, July 2025, Taylor & Francis

    Dr Jonathan G Pol

  2. Lysosomal membrane permeabilization enhances the anticancer effects of POLR1 (RNA polymerase I) transcription inhibitors

    Article • Autophagy, June 2025, Taylor & Francis

    Dr Jonathan G Pol

  3. Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade

    Article • Journal for ImmunoTherapy of Cancer, June 2025, BMJ

    Dr Jonathan G Pol

  4. Lysosomal membrane permeabilization enhances the anticancer effects of RNA Polymerase I transcription inhibitors

    Article • March 2025, Cold Spring Harbor Laboratory Press

    Dr Jonathan G Pol

  5. Epigenetic regulation of HOXA2 expression affects tumor progression and predicts breast cancer patient survival

    Article • Cell Death and Differentiation, January 2025, Springer Science + Business Media

    Dr Jonathan G Pol

  6. RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome

    Article • OncoImmunology, November 2024, Taylor & Francis

    Dr Jonathan G Pol

  7. Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

    Article • OncoImmunology, July 2024, Taylor & Francis

    Dr Jonathan G Pol

  8. Immunogenic oncolysis by tigilanol tiglate

    Article • OncoImmunology, May 2024, Taylor & Francis

    Dr Jonathan G Pol

  9. Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management

    Article • Gut, April 2024, BMJ

    Dr Jonathan G Pol

  10. Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity

    Article • OncoImmunology, January 2024, Taylor & Francis

    Dr Jonathan G Pol

  11. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses

    Article • Journal for ImmunoTherapy of Cancer, July 2023, BMJ

    Dr Jonathan G Pol

  12. Systematic Investigation of the Diagnostic and Prognostic Impact of LINC01087 in Human Cancers

    Article • Cancers, December 2022, MDPI AG

    Dr Jonathan G Pol

  13. PDIA3 as a potential bridge between immunogenic cell death and autoreactivity

    Article • OncoImmunology, September 2022, Taylor & Francis

    Dr Jonathan G Pol

  14. Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer

    Article • Journal for ImmunoTherapy of Cancer, June 2022, BMJ

    Dr Jonathan G Pol

  15. Circular RNAs as Potential Biomarkers in Breast Cancer

    Article • Biomedicines, March 2022, MDPI AG

    Dr Jonathan G Pol

  16. Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases

    Article • OncoImmunology, January 2022, Taylor & Francis

    Dr Jonathan G Pol

  17. Improved Swiss-rolling method for histological analyses of colon tissue

    Article • MethodsX, January 2022, Elsevier

    Dr Jonathan G Pol

  18. Alternative splicing of viral transcripts: the dark side of HBV

    Article • Gut, September 2021, BMJ

    Dr Jonathan G Pol

  19. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma

    Article • Journal of Experimental Medicine, September 2021, Rockefeller University Press

    Dr Jonathan G Pol

  20. L’interaction HMGB1/tétranectine

    Article • médecine/sciences, August 2021, EDP Sciences

    Dr Jonathan G Pol

  21. Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy

    Article • Cancers, March 2021, MDPI AG

    Dr Jonathan G Pol

  22. A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

    Article • Cancer Discovery, February 2021, American Association for Cancer Research (AACR)

    Dr Jonathan G Pol

  23. Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma

    Article • OncoImmunology, January 2021, Taylor & Francis

    Dr Jonathan G Pol

  24. Trial watch: intratumoral immunotherapy

    Article • OncoImmunology, January 2021, Taylor & Francis

    Dr Jonathan G Pol

  25. Tumor-intrinsic determinants of immunogenic cell death modalities

    Article • OncoImmunology, January 2021, Taylor & Francis

    Dr Jonathan G Pol

  26. Cytokines in oncolytic virotherapy

    Article • Cytokine & Growth Factor Reviews, December 2020, Elsevier

    Dr Jonathan G Pol

  27. Autophagy-mediated metabolic effects of aspirin

    Article • Cell Death Discovery, November 2020, Springer Science + Business Media

    Dr Jonathan G Pol

  28. Dynamical Boolean Modeling of Immunogenic Cell Death

    Article • Frontiers in Physiology, November 2020, Frontiers

    Dr Jonathan G Pol

  29. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome

    Article • Pharmacological Research, November 2020, Elsevier

    MD, PhD Valeria D'Argenio, Dr Jonathan G Pol

  30. Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

    Article • Nature Communications, September 2020, Springer Science + Business Media

    Dr Jonathan G Pol

  31. Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning

    Article • Journal for ImmunoTherapy of Cancer, August 2020, BMJ

    Dr Jonathan G Pol

  32. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

    Article • Nature Communications, July 2020, Springer Science + Business Media

    Dr Jonathan G Pol

  33. Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)

    Article • Cell Death and Disease, July 2020, Springer Science + Business Media

    Dr Jonathan G Pol

  34. Le jeûne réduit l’inflammation associée aux maladies inflammatoires chroniques sans altérer la réponse immunitaire aux infections aiguës

    Article • médecine/sciences, June 2020, EDP Sciences

    Dr Jonathan G Pol

  35. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress

    Article • EMBO Molecular Medicine, April 2020, Springer Science + Business Media

    Dr Jonathan G Pol

  36. Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy

    Article • Journal for ImmunoTherapy of Cancer, March 2020, BMJ

    Dr Jonathan G Pol

  37. Immune contexture of cholangiocarcinoma

    Article • Current Opinion in Gastroenterology, March 2020, Wolters Kluwer Health

    Dr Jonathan G Pol

  38. Repurposing CD8 + T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

    Article • OncoImmunology, January 2020, Taylor & Francis

    Dr Jonathan G Pol

  39. FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin

    Article • OncoImmunology, January 2020, Taylor & Francis

    Dr Jonathan G Pol

  40. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity

    Article • Cell Metabolism, December 2019, Elsevier

    Dr Jonathan G Pol

  41. Effects of interleukin-2 in immunostimulation and immunosuppression

    Article • Journal of Experimental Medicine, October 2019, Rockefeller University Press

    Dr Jonathan G Pol

  42. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity

    Article • Cell Metabolism, October 2019, Elsevier

    Professor Nektarios Tavernarakis, Dr Jonathan G Pol

  43. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice

    Article • OncoImmunology, September 2019, Taylor & Francis

    Dr Jonathan G Pol, Prof. Guido Kroemer

  44. Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination

    Article • September 2019, Springer Science + Business Media

    Dr Jonathan G Pol

  45. The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer

    Article • Cancers, July 2019, MDPI AG

    MD, PhD Valeria D'Argenio, Dr Jonathan G Pol

  46. Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer

    Article • Nature Communications, April 2019, Springer Science + Business Media

    Dr Jonathan G Pol

  47. Tumor lysis with LTX-401 creates anticancer immunity

    Article • OncoImmunology, April 2019, Taylor & Francis

    Dr Jonathan G Pol, Prof. Guido Kroemer

  48. Trial watch: dietary interventions for cancer therapy

    Article • OncoImmunology, April 2019, Taylor & Francis

    Dr Jonathan G Pol, FERRERE Gladys, Prof. Guido Kroemer

  49. Crizotinib-induced immunogenic cell death in non-small cell lung cancer

    Article • Nature Communications, April 2019, Springer Science + Business Media

    Dr Jonathan G Pol

  50. Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate

    Article • Cell Reports, April 2019, Elsevier

    Dr Jonathan G Pol

  51. Développement de traitements anticancéreux associant chimio-immunothérapie et composés mimétiques de la restriction calorique

    Article • HEGEL - HEpato-GastroEntérologie Libérale, January 2019, CAIRN

    Dr Jonathan G Pol

  52. Anticancer effects of anti-CD47 immunotherapy in vivo

    Article • OncoImmunology, December 2018, Taylor & Francis

    Dr Jonathan G Pol, Prof. Guido Kroemer

  53. Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models

    Article • November 2018, Springer Science + Business Media

    Dr Jonathan G Pol

  54. Development and applications of oncolytic Maraba virus vaccines

    Article • Oncolytic Virotherapy, November 2018, Dove Medical Press

    Dr Jonathan G Pol, Mathieu Crupi, Kyle Stephenson

  55. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

    Article • OncoImmunology, September 2018, Taylor & Francis

    Dr Sergio A Acuna, Dr Jonathan G Pol, Mathieu Crupi, Dr Brian Lichty, Robin Parsons

  56. Trial watch: peptide-based vaccines in anticancer therapy

    Article • OncoImmunology, September 2018, Taylor & Francis

    Dr Jonathan G Pol, Prof. Guido Kroemer

  57. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

    Article • OncoImmunology, August 2018, Taylor & Francis

    Dr Jonathan G Pol, Mathieu Crupi, Prof. Guido Kroemer

  58. HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants

    Article • Cell Reports, July 2018, Elsevier

    Dr Jonathan G Pol

  59. Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts

    Article • OncoImmunology, June 2018, Taylor & Francis

    Prof. Guido Kroemer , Dr Jonathan G Pol

  60. Metabolic vulnerability of cisplatin‐resistant cancers

    Article • The EMBO Journal, June 2018, Springer Science + Business Media

    Dr Jonathan G Pol

  61. Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy

    Article • Frontiers in Immunology, April 2018, Frontiers

    Dr Jonathan G Pol

  62. Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

    Article • BDJ, March 2018, Springer Science + Business Media

    Dr Jonathan G Pol

  63. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

    Article • Trends in Immunology, March 2018, Elsevier

    Dr Jonathan G Pol

  64. Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies

    Article • OncoImmunology, February 2018, Taylor & Francis

    Dr Jonathan G Pol, Prof. Guido Kroemer

  65. Trial watch: DNA-based vaccines for oncological indications

    Article • OncoImmunology, November 2017, Taylor & Francis

    Dr Jonathan G Pol

  66. Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance

    Article • Immunological Reviews, October 2017, Wiley

    Dr Jonathan G Pol

  67. Customized Viral Immunotherapy for HPV-Associated Cancer

    Article • Cancer Immunology Research, October 2017, American Association for Cancer Research (AACR)

    Dr Jonathan G Pol

  68. Metabolic effects of fasting on human and mouse blood in vivo

    Article • Autophagy, February 2017, Taylor & Francis

    Dr Jonathan G Pol

  69. Fasting improves anticancer immunosurveillance via autophagy induction in malignant cells

    Article • Cell Cycle, September 2016, Taylor & Francis

    Dr Jonathan G Pol

  70. Autophagy induction for the treatment of cancer

    Article • Autophagy, September 2016, Taylor & Francis

    Dr Jonathan G Pol

  71. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance

    Article • Cancer Cell, July 2016, Elsevier

    Dr Jonathan G Pol

  72. Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination

    Article • The Journal of Immunology, June 2016, Oxford University Press (OUP)

    Dr Jonathan G Pol

  73. S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3

    Article • Nature Immunology, April 2016, Springer Science + Business Media

    Dr Jonathan G Pol

  74. First oncolytic virus approved for melanoma immunotherapy

    Article • OncoImmunology, December 2015, Taylor & Francis

    Dr Jonathan G Pol

  75. Trial Watch—Oncolytic viruses and cancer therapy

    Article • OncoImmunology, December 2015, Taylor & Francis

    Dr Jonathan G Pol

  76. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

    Article • OncoImmunology, March 2015, Taylor & Francis

    Dr Jonathan G Pol

  77. Alternative splicing‐regulated protein of hepatitis B virus hacks the TNF‐α‐stimulated signaling pathways and limits the extent of liver inflammation

    Article • The FASEB Journal, January 2015, Wiley

    Dr Jonathan G Pol

  78. Trial Watch: Peptide-based anticancer vaccines

    Article • OncoImmunology, January 2015, Taylor & Francis

    Dr Jonathan G Pol

  79. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

    Article • OncoImmunology, January 2015, Taylor & Francis

    Dr Jonathan G Pol

  80. Trial watch: Dendritic cell-based anticancer therapy

    Article • OncoImmunology, November 2014, Taylor & Francis

    Dr Jonathan G Pol

  81. Trial Watch: Radioimmunotherapy for oncological indications

    Article • OncoImmunology, September 2014, Taylor & Francis

    Dr Jonathan G Pol

  82. Consensus guidelines for the detection of immunogenic cell death

    Article • OncoImmunology, September 2014, Taylor & Francis

    Dr Jonathan G Pol, Abhishek Garg

  83. Trial Watch:

    Article • OncoImmunology, June 2014, Taylor & Francis

    Dr Jonathan G Pol

  84. Trial Watch

    Article • OncoImmunology, April 2014, Taylor & Francis

    Dr Jonathan G Pol

  85. Maraba Virus as a Potent Oncolytic Vaccine Vector

    Article • February 2014, Elsevier

    Dr Jonathan G Pol

  86. Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy

    Article • Molecular Therapy, January 2014, Elsevier

    Dr Jonathan G Pol

  87. Panorama From the Oncolytic Virotherapy Summit

    Article • Molecular Therapy, October 2013, Elsevier

    Dr Jonathan G Pol

  88. Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy

    Article • Cancer Immunology Research, August 2013, American Association for Cancer Research (AACR)

    Dr Jonathan G Pol

  89. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines

    Article • OncoImmunology, August 2013, Taylor & Francis

    Dr Jonathan G Pol

  90. HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy

    Article • Molecular Therapy, April 2013, Elsevier

    Dr Jonathan G Pol

  91. Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses

    Article • Blood, March 2013, American Society of Hematology

    Dr Jonathan G Pol

  92. Stratégies génétiques, immunologiques et pharmacologiques au service d’une nouvelle génération de virus anticancéreux

    Article • médecine/sciences, February 2013, EDP Sciences

    Dr Jonathan G Pol

  93. Oncolytic viruses: a step into cancer immunotherapy.

    Article • Virus Adaptation and Treatment, December 2011, Taylor & Francis

    Dr Jonathan G Pol, Dr Brian Lichty

  94. Prospective comparison of Abbott RealTime HBV DNA and Versant HBV DNA 3.0 assays for hepatitis B DNA quantitation: Impact on HBV genotype monitoring

    Article • Journal of Virological Methods, December 2008, Elsevier

    Dr Jonathan G Pol

  95. Expression of Defective Hepatitis B Virus Particles Derived from Singly Spliced RNA Is Related to Liver Disease

    Article • The Journal of Infectious Diseases, July 2008, Oxford University Press (OUP)

    Dr Jonathan G Pol

  96. P.053 Spliced hepatitis B virus RNA and liver disease

    Article • Journal of Clinical Virology, January 2006, Elsevier

    Dr Jonathan G Pol